{"paper_id": "c43a3b4959333a6f578d5b194fda5ab6e0332a7c", "metadata": {"title": "Journal Pre-proofs Review Management guidelines for pregnant healthcare workers exposed to infectious dermatoses Title: Management guidelines for pregnant healthcare workers exposed to infectious dermatoses Introduction", "authors": [{"first": "Vidhatha", "middle": [], "last": "Reddy", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of California", "location": {"settlement": "San Francisco, San Francisco", "region": "CA"}}, "email": "vidhatha.reddy@ucsf.edu"}, {"first": "Alexander", "middle": ["L"], "last": "Kollhoff", "suffix": "", "affiliation": {"laboratory": "", "institution": "Augusta University/University of Georgia Medical Partnership", "location": {"settlement": "Athens", "region": "GA"}}, "email": ""}, {"first": "Jenny", "middle": ["E"], "last": "Murase", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of California", "location": {"settlement": "San Francisco, San Francisco", "region": "CA"}}, "email": ""}, {"first": "Kathryn", "middle": [], "last": "Martires", "suffix": "", "affiliation": {"laboratory": "Palo Alto Foundation Medical Group", "institution": "Vidhatha Reddy", "location": {"addrLine": "BA Address: 515 Spruce Street San Francisco", "postCode": "94118", "settlement": "Mountain View", "region": "CA, CA"}}, "email": ""}, {"first": "B", "middle": ["A"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "B", "middle": ["S"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "M", "middle": ["D"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "M", "middle": ["D"], "last": "Affiliation", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "Exanthematous diseases are frequently of infectious origin, posing risks, especially for 3 pregnant healthcare workers (HCWs) who treat them. The shift from cell-mediated (Th1 4 cytokine profile) to humoral (Th2 cytokine profile) immunity during pregnancy can influence the 5 mother's susceptibility to infection and lead to complications for both mother and fetus. The 6 potential for vertical transmission must be considered when evaluating the risks for pregnant 7 HCWs treating infected patients, as fetal infection can often have devastating consequences. 8 Given the high proportion of women of childbearing age among HCWs, the pregnancy-related 9 risks of infectious exposure are an important topic in both patient care and occupational health.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "10 Contagious patients with cutaneous manifestations often present to dermatology or pediatric 11 clinics, where female providers are particularly prevalent, as a growing number of these 12 physicians are female. Unfortunately, the risks of infection for pregnant HCWs are not well 13 defined. To our knowledge, there is limited guidance on safe practices for pregnant HCWs who 14 encounter infectious dermatologic diseases. In this article, we review several infectious 15 exanthems, their transmissibility to pregnant women, the likelihood of vertical transmission, and 16", "cite_spans": [], "ref_spans": [], "section": "Abstract"}, {"text": "the potential consequences of infection for the mother and the fetus. Additionally, we discuss 17 recommendations with respect to avoidance, contact and respiratory precautions, and the need 18 for treatment following exposure.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "HCWs. This review identifies various infectious exanthems that pregnant HCWs may be exposed 30 to and summarizes current available evidence regarding risk of transmission. Specifically, we 31 discuss parvovirus B19, hand, foot and mouth disease, mycoplasma-induced rash and mucositis, 32 measles, herpes simplex virus, varicella-zoster virus, and pityriasis rosea. We also provide 33 guidelines for each disease in order for pregnant HCWs and HCWs of reproductive potential to 34 appropriately minimize risk and pursue work-up and treatment, if necessary, following exposure. 35 Finally, given the ongoing global coronavirus disease 2019 (COVID-19) pandemic caused by 36 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), we also summarize available 37 safety guidelines for pregnant HCWs who are working during this time. 59 Data on the risk of transmission to HCWs, however, is conflicting (Adler et al., 1993) . following exposure to infected patients. One single-center study at Children's Hospital of 63 Philadelphia found elevated risk of infection between exposed and unexposed staff (Bell et al., 64 1998 ). However, a cohort study of 87 HCWs exposed to two patients with parvovirus B19-65 induced aplastic crisis found no significant increase in parvovirus B19-specific immunoglobulin 66 M (IgM) and immunoglobulin G (IgG) antibodies when compared with unexposed health care 67 workers in the same facility (Ray et al., 1997) .", "cite_spans": [{"start": 92, "end": 94, "text": "30", "ref_id": null}, {"start": 477, "end": 479, "text": "34", "ref_id": null}, {"start": 576, "end": 578, "text": "35", "ref_id": null}, {"start": 834, "end": 836, "text": "59", "ref_id": null}, {"start": 903, "end": 923, "text": "(Adler et al., 1993)", "ref_id": null}, {"start": 1017, "end": 1019, "text": "63", "ref_id": null}, {"start": 1102, "end": 1123, "text": "(Bell et al., 64 1998", "ref_id": null}, {"start": 1427, "end": 1445, "text": "(Ray et al., 1997)", "ref_id": "BIBREF87"}], "ref_spans": [], "section": ""}, {"text": "While the risk of transmission to HCWs has not been definitively identified, preventing 69 the transmission of PVB19 infection is important as it can lead to adverse pregnancy outcomes.", "cite_spans": [], "ref_spans": [], "section": "68"}, {"text": "PVB19 infection carries a 9% excess risk of miscarriage within the first 20 weeks of gestation, 71 and 2.9% risk of fetal hydrops between weeks 9 and 20 (Miller et al., 1998 vesicular rash affecting the hands, feet, and oral mucosa. As one of the most common pediatric 91 exanthems, HFMD is routinely seen by pediatric and dermatology HCWs, presenting a potential 92 concern for occupational exposure. ", "cite_spans": [{"start": 96, "end": 98, "text": "71", "ref_id": null}, {"start": 153, "end": 173, "text": "(Miller et al., 1998", "ref_id": "BIBREF65"}, {"start": 364, "end": 366, "text": "92", "ref_id": "BIBREF98"}], "ref_spans": [], "section": "70"}, {"text": "All HCWs who are exposed to VZV should be monitored daily during days 8-21 after ", "cite_spans": [], "ref_spans": [], "section": "294"}, {"text": "The etiology of PR is unclear. Various clinical and epidemiological features of PR 318 support a viral origin, including its self-limiting course, low recurrence rate, occasional 319 household clustering, possible seasonal variation, prodromal symptoms, response to acyclovir, 320 and higher prevalence during states of impaired immunity (e.g., pregnancy). There is a well-321 established association between PR and human herpesviruses 6 and 7 (HHV-6/7) (Drago et al., Since PR is self-limiting, management is generally limited to reassurance and the 360 treatment of symptoms with emollients, antihistamines, and occasionally topical steroids. when caring for patients with PR. Although PR is not thought to be contagious, and women of 374 childbearing age have likely already been exposed to HHV-6/7, this recommendation is based 375 upon the uncertainty surrounding its etiology and the potential danger of infection to the fetus. ", "cite_spans": [], "ref_spans": [], "section": "317"}, {"text": "Both pregnant HCWs and patients have expressed concern regarding potential complications 387 from COVID-19, although the disease appears to disproportionately affect men compared to The CDC's recommendations for the vaccination of HCWs are summarized in Table 3 . ", "cite_spans": [], "ref_spans": [{"start": 254, "end": 261, "text": "Table 3", "ref_id": null}], "section": "386"}], "bib_entries": {"BIBREF1": {"ref_id": "b1", "title": "Parvovirus B19 Infections among School and Hospital Employees during Endemic Periods", "authors": [], "year": null, "venue": "J Infect Dis", "volume": "451", "issn": "", "pages": "361--368", "other_ids": {"DOI": ["10.1093/infdis/168.2.361"]}}, "BIBREF2": {"ref_id": "b2", "title": "Pityriasis rosea-like eruption associated with ondansetron use in 453 pregnancy", "authors": [{"first": "M", "middle": ["M"], "last": "Alame", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Chamsy", "suffix": ""}, {"first": "H", "middle": [], "last": "Zaraket", "suffix": ""}], "year": 2018, "venue": "British Journal of Clinical Pharmacology", "volume": "84", "issn": "5", "pages": "1077--1080", "other_ids": {"DOI": ["10.1111/bcp.13560"]}}, "BIBREF3": {"ref_id": "b3", "title": "Measles in pregnancy: Maternal morbidity and perinatal outcome", "authors": [{"first": "M", "middle": ["E"], "last": "Ali", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Albar", "suffix": ""}], "year": null, "venue": "Int J Gynaecol", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Immunization in special clinical circumstances", "authors": [], "year": null, "venue": "American Academy of Pediatrics", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "Red 460 book: 2012 report of the Committee on Infectious Diseases", "authors": [{"first": "L", "middle": ["K"], "last": "Pickering", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Baker", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Kimberlin", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Long", "suffix": ""}], "year": null, "venue": "", "volume": "2012", "issn": "", "pages": "489--499", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Varicella-zoster infections", "authors": [{"first": "L", "middle": ["K"], "last": "Pickering", "suffix": ""}, {"first": "C", "middle": ["J"], "last": "Baker", "suffix": ""}, {"first": "D", "middle": ["W"], "last": "Kimberlin", "suffix": ""}], "year": null, "venue": "American Academy of Pediatrics", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Red book: 2012 report of the Committee on Infectious Diseases", "authors": [{"first": "S", "middle": ["S"], "last": "Long", "suffix": ""}], "year": null, "venue": "", "volume": "2012", "issn": "", "pages": "774--89", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Notes from the Field: Outbreak of Hand, Foot, and Mouth Disease Caused by 468", "authors": [{"first": "J", "middle": [], "last": "Banta", "suffix": ""}], "year": 2016, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Coxsackievirus A6 Among Basic Military Trainees -Texas", "authors": [], "year": 2015, "venue": "", "volume": "65", "issn": "", "pages": "", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Pregnancy outcome following rubella 471 vaccination: A prospective controlled study", "authors": [{"first": "B", "middle": [], "last": "Bar-Oz", "suffix": ""}, {"first": "Z", "middle": [], "last": "Levichek", "suffix": ""}, {"first": "M", "middle": ["E"], "last": "Moretti", "suffix": ""}, {"first": "C", "middle": [], "last": "Mah", "suffix": ""}, {"first": "S", "middle": [], "last": "Andreou", "suffix": ""}, {"first": "G", "middle": [], "last": "Koren", "suffix": ""}], "year": 2004, "venue": "American Journal of Medical Genetics Part A", "volume": "472", "issn": "1", "pages": "52--54", "other_ids": {"DOI": ["10.1002/ajmg.a.30225"]}}, "BIBREF15": {"ref_id": "b15", "title": "Human Parvo Virus B19 474 Infection among Hospital Staff Members after Contact with Infected Patients", "authors": [{"first": "L", "middle": ["M"], "last": "Bell", "suffix": ""}, {"first": "S", "middle": ["J"], "last": "Naides", "suffix": ""}, {"first": "P", "middle": [], "last": "Stoffman", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Hodinka", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Plotkin", "suffix": ""}], "year": 1989, "venue": "New England Journal", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "Guideline for 479 infection control in healthcare personnel", "authors": [{"first": "E", "middle": ["A"], "last": "Bolyard", "suffix": ""}, {"first": "O", "middle": ["C"], "last": "Tablan", "suffix": ""}, {"first": "W", "middle": ["W"], "last": "Williams", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Pearson", "suffix": ""}, {"first": "C", "middle": ["N"], "last": "Shapiro", "suffix": ""}, {"first": "S", "middle": ["D"], "last": "Deitchmann", "suffix": ""}], "year": 1998, "venue": "Hospital Infection Control Practices Advisory Committee", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "Additional evidence that pityriasis rosea is associated with 482 reactivation of human herpesvirus-6 and -7", "authors": [{"first": "F", "middle": [], "last": "Broccolo", "suffix": ""}, {"first": "F", "middle": [], "last": "Drago", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Careddu", "suffix": ""}], "year": 2005, "venue": "J Invest Dermatol", "volume": "124", "issn": "", "pages": "", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "The Acquisition of Herpes Simplex Virus during Pregnancy", "authors": [{"first": "Z", "middle": ["A"], "last": "Brown", "suffix": ""}, {"first": "S", "middle": [], "last": "Selke", "suffix": ""}, {"first": "J", "middle": [], "last": "Zeh", "suffix": ""}], "year": null, "venue": "N Engl J", "volume": "484", "issn": "", "pages": "", "other_ids": {}}, "BIBREF25": {"ref_id": "b25", "title": "Mouth Disease Caused by Coxsackievirus A6--Minnesota", "authors": [], "year": 2014, "venue": "MMWR Morb. Mortal", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF27": {"ref_id": "b27", "title": "Mycoplasma pneumoniae-induced rash and 489 mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic 490 review", "authors": [{"first": "T", "middle": ["N"], "last": "Canavan", "suffix": ""}, {"first": "E", "middle": ["F"], "last": "Mathes", "suffix": ""}, {"first": "I", "middle": [], "last": "Frieden", "suffix": ""}, {"first": "K", "middle": [], "last": "Shinkai", "suffix": ""}], "year": 2015, "venue": "J. Am. Acad. Dermatol", "volume": "72", "issn": "", "pages": "239--245", "other_ids": {"DOI": ["10.1016/j.jaad.2014.06.026"]}}, "BIBREF28": {"ref_id": "b28", "title": "Early Developmental Outcomes of Children With Congenital 492 HHV-6 Infection", "authors": [{"first": "M", "middle": ["T"], "last": "Caserta", "suffix": ""}, {"first": "C", "middle": ["B"], "last": "Hall", "suffix": ""}, {"first": "R", "middle": ["L"], "last": "Canfield", "suffix": ""}], "year": 2014, "venue": "Pediatrics", "volume": "134", "issn": "6", "pages": "1111--1118", "other_ids": {"DOI": ["10.1542/peds.2014-0886"]}}, "BIBREF30": {"ref_id": "b30", "title": "Infections in Pregnant Women. The Journal of Infectious Diseases", "authors": [], "year": 2007, "venue": "", "volume": "196", "issn": "", "pages": "1296--303", "other_ids": {}}, "BIBREF31": {"ref_id": "b31", "title": "Interim Infection Prevention and Control Recommendations 496 for Measles in Healthcare Settings", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF34": {"ref_id": "b34", "title": "Transmission and Clinical Features of Enterovirus 71 Infections in 500", "authors": [{"first": "Y.-C", "middle": [], "last": "Huang", "suffix": ""}, {"first": "T.-Y", "middle": [], "last": "Lin", "suffix": ""}], "year": 2004, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF35": {"ref_id": "b35", "title": "Household Contacts in Taiwan", "authors": [], "year": 2002, "venue": "Obstet Gynecol", "volume": "291", "issn": "2", "pages": "260--265", "other_ids": {"DOI": ["10.1001/jama.291.2.222579cohortof347pregnantwomen"]}}, "BIBREF36": {"ref_id": "b36", "title": "Human parvovirus B19 infection in healthcare workers", "authors": [{"first": "J", "middle": [], "last": "Harrison", "suffix": ""}, {"first": "C", "middle": ["E"], "last": "Jones", "suffix": ""}], "year": 1995, "venue": "Occup Med (Lond)", "volume": "581", "issn": "", "pages": "93--96", "other_ids": {"DOI": ["10.1093/occmed/45.2.93"]}}, "BIBREF38": {"ref_id": "b38", "title": "Placental Massive Perivillous Fibrinoid Deposition Associated with 584", "authors": [{"first": "A", "middle": [], "last": "Denison", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Zaki", "suffix": ""}], "year": 2016, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF39": {"ref_id": "b39", "title": "Report of a Case, and Review of the Literature", "authors": [{"first": "A16", "middle": [], "last": "Coxsackievirus", "suffix": ""}], "year": null, "venue": "Pediatr Dev Pathol", "volume": "19", "issn": "", "pages": "421--423", "other_ids": {}}, "BIBREF41": {"ref_id": "b41", "title": "Atypical Hand, Foot, and Mouth Disease Caused by 587", "authors": [{"first": "H", "middle": [], "last": "Horsten", "suffix": ""}, {"first": "M", "middle": [], "last": "Kemp", "suffix": ""}, {"first": "T", "middle": [], "last": "Fischer", "suffix": ""}, {"first": "K", "middle": [], "last": "Lindahl", "suffix": ""}, {"first": "A", "middle": [], "last": "Bygum", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF42": {"ref_id": "b42", "title": "Parvovirus B19: a review", "authors": [{"first": "; A Diagnostic", "middle": [], "last": "Coxsackievirus A6 In Denmark", "suffix": ""}, {"first": ";", "middle": ["R"], "last": "Mimicker", "suffix": ""}], "year": 2002, "venue": "Dermatologic Clinics", "volume": "98", "issn": "3", "pages": "333--342", "other_ids": {"DOI": ["10.2340/00015555-2853Katta"]}}, "BIBREF44": {"ref_id": "b44", "title": "Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization 591 Practices (ACIP)", "authors": [], "year": 2011, "venue": "MMWR", "volume": "", "issn": "RR07", "pages": "1--45", "other_ids": {}}, "BIBREF45": {"ref_id": "b45", "title": "Association of COVID-19 infection with pregnancy outcomes in 594 healthcare workers and general women. Clinical Microbiology and Infection", "authors": [{"first": "S", "middle": [], "last": "Khan", "suffix": ""}, {"first": "L", "middle": [], "last": "Jun", "suffix": ""}, {"first": "", "middle": [], "last": "Nawsherwan", "suffix": ""}], "year": 2020, "venue": "", "volume": "595", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.cmi.2020.03.034"]}}, "BIBREF46": {"ref_id": "b46", "title": "Management of an obstetric health care provider with acute 597 parvovirus B19 infection", "authors": [{"first": "K", "middle": ["A"], "last": "Kho", "suffix": ""}, {"first": "K", "middle": [], "last": "Eisinger", "suffix": ""}, {"first": "K", "middle": ["T"], "last": "Chen", "suffix": ""}], "year": 2008, "venue": "American Journal of Obstetrics and Gynecology", "volume": "198", "issn": "", "pages": "33--34", "other_ids": {}}, "BIBREF48": {"ref_id": "b48", "title": "Implementation of Hospital Policy for Healthcare Workers and 600 Patients Exposed to Varicella-Zoster Virus", "authors": [{"first": "S-H", "middle": [], "last": "Kim", "suffix": ""}, {"first": "S", "middle": ["H"], "last": "Park", "suffix": ""}, {"first": "S-M", "middle": [], "last": "Choi", "suffix": ""}, {"first": "D-G", "middle": [], "last": "Lee", "suffix": ""}], "year": 2018, "venue": "J Korean Med Sci", "volume": "33", "issn": "36", "pages": "", "other_ids": {"DOI": ["10.3346/jkms.2018.33.e252"]}}, "BIBREF49": {"ref_id": "b49", "title": "Hand-foot-and-mouth disease caused by coxsackievirus A6 on the 603 rise", "authors": [{"first": "D", "middle": ["B"], "last": "Kimmis", "suffix": ""}, {"first": "C", "middle": [], "last": "Downing", "suffix": ""}, {"first": "S", "middle": [], "last": "Tyring", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF50": {"ref_id": "b50", "title": "A case-controlled study comparing clinical course and outcomes of 606 pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG: An International 607", "authors": [{"first": "C", "middle": ["M"], "last": "Lam", "suffix": ""}, {"first": "S", "middle": ["F"], "last": "Wong", "suffix": ""}, {"first": "T", "middle": ["N"], "last": "Leung", "suffix": ""}], "year": 2004, "venue": "Journal of Obstetrics & Gynaecology", "volume": "111", "issn": "8", "pages": "771--774", "other_ids": {"DOI": ["10.1111/j.1471-0528.2004.00199.x608"]}}, "BIBREF52": {"ref_id": "b52", "title": "Parvovirus B19 Infection in Human Pregnancy", "authors": [{"first": "R", "middle": [], "last": "", "suffix": ""}], "year": 2011, "venue": "BJOG", "volume": "118", "issn": "", "pages": "175--186", "other_ids": {}}, "BIBREF54": {"ref_id": "b54", "title": "Outbreak of parvovirus B19 infection among anesthesiology and surgical fellows", "authors": [{"first": "A", "middle": [], "last": "", "suffix": ""}], "year": 2016, "venue": "Am J Infect 613 Control", "volume": "44", "issn": "", "pages": "1069--1070", "other_ids": {"DOI": ["10.1016/j.ajic.2015.12.004"]}}, "BIBREF55": {"ref_id": "b55", "title": "Association of State Laws", "authors": [{"first": "C", "middle": ["J"], "last": "Lin", "suffix": ""}, {"first": "M", "middle": ["P"], "last": "Nowalk", "suffix": ""}, {"first": "Raymund", "middle": ["M"], "last": "Sweeney", "suffix": ""}, {"first": "P", "middle": ["M"], "last": "Zimmerman", "suffix": ""}, {"first": "R", "middle": ["K"], "last": "", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF56": {"ref_id": "b56", "title": "Healthcare Workers' Influenza Vaccination Rates", "authors": [], "year": 2016, "venue": "Journal of the National Medical Association", "volume": "616", "issn": "1", "pages": "99--102", "other_ids": {"DOI": ["10.1016/j.jnma.2015.12.013"]}}, "BIBREF57": {"ref_id": "b57", "title": "Clinical manifestations and outcome of SARS-CoV-2 infection during 618 pregnancy", "authors": [{"first": "Y", "middle": [], "last": "Liu", "suffix": ""}, {"first": "H", "middle": [], "last": "Chen", "suffix": ""}, {"first": "K", "middle": [], "last": "Tang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Guo", "suffix": ""}], "year": 2020, "venue": "Journal of Infection", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.jinf.2020.02.028"]}}, "BIBREF58": {"ref_id": "b58", "title": "Pityriasis rosea: An update on etiopathogenesis and 620 management of difficult aspects", "authors": [{"first": "K", "middle": [], "last": "Mahajan", "suffix": ""}, {"first": "V", "middle": [], "last": "Relhan", "suffix": ""}, {"first": "A", "middle": ["K"], "last": "Relhan", "suffix": ""}, {"first": "V", "middle": ["K"], "last": "Garg", "suffix": ""}], "year": 2016, "venue": "Indian Journal of Dermatology", "volume": "61", "issn": "4", "pages": "", "other_ids": {"DOI": ["10.4103/0019-621"]}}, "BIBREF59": {"ref_id": "b59", "title": "Updated recommendations for use of VariZIG -United States", "authors": [{"first": "M", "middle": [], "last": "Marin", "suffix": ""}, {"first": "S", "middle": ["R"], "last": "Bialek", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "Seward", "suffix": ""}], "year": 2013, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF61": {"ref_id": "b61", "title": "A report of three cases and review of intrauterine herpes 625 simplex virus infection", "authors": [{"first": "L", "middle": [], "last": "Marquez", "suffix": ""}, {"first": "M", "middle": ["L"], "last": "Levy", "suffix": ""}, {"first": "F", "middle": ["M"], "last": "Munoz", "suffix": ""}, {"first": "D", "middle": ["L"], "last": "Palazzi", "suffix": ""}], "year": 2011, "venue": "Pediatr Infect Dis J", "volume": "30", "issn": "2", "pages": "153--157", "other_ids": {"DOI": ["10.1097/INF.0b013e3181f55a5c.626"]}}, "BIBREF62": {"ref_id": "b62", "title": "A Case of Macrolide-Refractory 627", "authors": [{"first": "Y", "middle": [], "last": "Matsuda", "suffix": ""}, {"first": "Y", "middle": [], "last": "Chigusa", "suffix": ""}, {"first": "E", "middle": [], "last": "Kondoh", "suffix": ""}, {"first": "I", "middle": [], "last": "Ito", "suffix": ""}, {"first": "Y", "middle": [], "last": "Ueda", "suffix": ""}, {"first": "M", "middle": [], "last": "Mandai", "suffix": ""}], "year": 2017, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF63": {"ref_id": "b63", "title": "Mycoplasma pneumoniae Pneumonia in Pregnancy Treated with Garenoxacin", "authors": [], "year": 2017, "venue": "Case Rep Obstet Gynecol", "volume": "628", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1155/2017/3520192"]}}, "BIBREF64": {"ref_id": "b64", "title": "Centers for Disease Control and Prevention. 630 Prevention of measles, rubella, congenital rubella syndrome, and mumps", "authors": [{"first": "H", "middle": ["Q"], "last": "Mclean", "suffix": ""}, {"first": "A", "middle": ["P"], "last": "Fiebelkorn", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Temte", "suffix": ""}, {"first": "G", "middle": ["S"], "last": "Wallace", "suffix": ""}], "year": 2013, "venue": "Summary 631 recommendations of the Advisory Committee on Immunization Practices (ACIP)", "volume": "632", "issn": "", "pages": "1--34", "other_ids": {}}, "BIBREF65": {"ref_id": "b65", "title": "Immediate and long term outcome of human 634 parvovirus B19 infection in pregnancy", "authors": [{"first": "E", "middle": [], "last": "Miller", "suffix": ""}, {"first": "C", "middle": ["K"], "last": "Fairley", "suffix": ""}, {"first": "B", "middle": ["J"], "last": "Cohen", "suffix": ""}, {"first": "C", "middle": [], "last": "Seng", "suffix": ""}], "year": 1998, "venue": "Br J Obstet Gynaecol", "volume": "105", "issn": "", "pages": "174--178", "other_ids": {}}, "BIBREF67": {"ref_id": "b67", "title": "Epidemiology, outcome and control of varicella-zoster infection", "authors": [{"first": "E", "middle": [], "last": "Miller", "suffix": ""}, {"first": "R", "middle": [], "last": "Marshall", "suffix": ""}, {"first": "J", "middle": [], "last": "Vurdien", "suffix": ""}], "year": null, "venue": "Rev Med", "volume": "637", "issn": "", "pages": "", "other_ids": {}}, "BIBREF69": {"ref_id": "b69", "title": "Gestational Pityriasis Rosea: Suggestions for 639", "authors": [{"first": "A", "middle": [], "last": "Monastirli", "suffix": ""}, {"first": "E", "middle": [], "last": "Pasmatzi", "suffix": ""}, {"first": "G", "middle": [], "last": "Badavanis", "suffix": ""}, {"first": "D", "middle": [], "last": "Tsambaos", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF70": {"ref_id": "b70", "title": "Approaching Affected Pregnant Women", "authors": [], "year": 2016, "venue": "Acta Dermatovenerologica Croatica", "volume": "24", "issn": "4", "pages": "312--313", "other_ids": {}}, "BIBREF71": {"ref_id": "b71", "title": "208-Guidelines for the Management of Herpes Simplex Virus in Pregnancy. 641 Journal of Obstetrics and Gynaecology Canada", "authors": [{"first": "D", "middle": ["M"], "last": "Money", "suffix": ""}, {"first": "M", "middle": [], "last": "Steben", "suffix": ""}, {"first": "", "middle": [], "last": "No", "suffix": ""}], "year": 2016, "venue": "M\u00fcllegger RR, H\u00e4ring NS, Glatz M", "volume": "39", "issn": "", "pages": "368--377", "other_ids": {"DOI": ["10.1016/j.jogc.2017.04.01664272"]}}, "BIBREF72": {"ref_id": "b72", "title": "Hand, Foot, and Mouth Disease in an Adult", "authors": [{"first": "C", "middle": [], "last": "Murase", "suffix": ""}, {"first": "M", "middle": [], "last": "Akiyama", "suffix": ""}], "year": 2018, "venue": "N. Engl. J. Med", "volume": "378", "issn": "20", "pages": "", "other_ids": {"DOI": ["10.1056/NEJMicm1713548"]}}, "BIBREF73": {"ref_id": "b73", "title": "TORCH infections", "authors": [{"first": "N", "middle": [], "last": "Neu", "suffix": ""}, {"first": "J", "middle": [], "last": "Duchon", "suffix": ""}, {"first": "P", "middle": [], "last": "Zachariah", "suffix": ""}], "year": 2015, "venue": "Clin Perinatol", "volume": "42", "issn": "", "pages": "77--103", "other_ids": {"DOI": ["10.1016/j.clp.2014.11.001"]}}, "BIBREF75": {"ref_id": "b75", "title": "Notes from the Field: Severe Hand, Foot, and Mouth Disease Associated with Coxsackievirus", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "6--651", "other_ids": {}}, "BIBREF77": {"ref_id": "b77", "title": "Maternal, fetal, and neonatal outcomes associated with measles during 654 pregnancy: Namibia", "authors": [{"first": "I", "middle": ["U"], "last": "Ogbuanu", "suffix": ""}, {"first": "S", "middle": [], "last": "Zeko", "suffix": ""}, {"first": "S", "middle": ["Y"], "last": "Chu", "suffix": ""}], "year": 2009, "venue": "Clinical Infectious Diseases", "volume": "58", "issn": "8", "pages": "1086--1092", "other_ids": {"DOI": ["10.1093/cid/ciu037"]}}, "BIBREF78": {"ref_id": "b78", "title": "Spontaneous abortion after hand-foot-and-mouth disease caused by 657", "authors": [{"first": "M", "middle": ["M"], "last": "Ogilvie", "suffix": ""}, {"first": "C", "middle": ["F"], "last": "Tearne", "suffix": ""}], "year": 1980, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF79": {"ref_id": "b79", "title": "Coxsackie virus A16", "authors": [], "year": null, "venue": "Br Med J", "volume": "281", "issn": "", "pages": "1527--1528", "other_ids": {"DOI": ["10.1136/bmj.281.6254.1527-a658"]}}, "BIBREF80": {"ref_id": "b80", "title": "Pityriasis rosea in pregnancy: a case report", "authors": [{"first": "R", "middle": ["W"], "last": "Overton", "suffix": ""}], "year": 1968, "venue": "Journal of the Iowa Medical Society", "volume": "58", "issn": "", "pages": "659--1239", "other_ids": {}}, "BIBREF81": {"ref_id": "b81", "title": "Outcome after Maternal Varicella Infection in the First 20 Weeks 661 of Pregnancy", "authors": [{"first": "A", "middle": ["L"], "last": "Pastuszak", "suffix": ""}, {"first": "M", "middle": [], "last": "Levy", "suffix": ""}, {"first": "B", "middle": [], "last": "Schick", "suffix": ""}], "year": 1994, "venue": "N Engl J Med", "volume": "330", "issn": "13", "pages": "901--905", "other_ids": {"DOI": ["10.1056/NEJM199403313301305"]}}, "BIBREF83": {"ref_id": "b83", "title": "Virus Infections in Neonates Exposed to the Virus at the Time of Vaginal Delivery to Mothers with 664 Recurrent Genital Herpes Simplex Virus Infections", "authors": [], "year": 1987, "venue": "N Engl J Med", "volume": "316", "issn": "5", "pages": "240--244", "other_ids": {"DOI": ["10.1056/NEJM198701293160503"]}}, "BIBREF85": {"ref_id": "b85", "title": "Coxsackievirus A6 associated hand, foot and mouth disease in adults: Clinical presentation and review of 668 the literature", "authors": [], "year": null, "venue": "Journal of Clinical Virology", "volume": "60", "issn": "", "pages": "381--386", "other_ids": {"DOI": ["10.1016/j.jcv.2014.04.023"]}}, "BIBREF86": {"ref_id": "b86", "title": "Coronavirus Disease 2019 (COVID-19) 670 and pregnancy: what obstetricians need to know", "authors": [{"first": "S", "middle": ["A"], "last": "Rasmussen", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Smulian", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Lednicky", "suffix": ""}, {"first": "T", "middle": ["S"], "last": "Wen", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Jamieson", "suffix": ""}], "year": 2020, "venue": "American Journal of Obstetrics and Gynecology", "volume": "671", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.ajog.2020.02.017"]}}, "BIBREF87": {"ref_id": "b87", "title": "Nosocomial 673 exposure to parvovirus B19: low risk of transmission to healthcare workers", "authors": [{"first": "S", "middle": ["M"], "last": "Ray", "suffix": ""}, {"first": "D", "middle": ["D"], "last": "Erdman", "suffix": ""}, {"first": "J", "middle": ["D"], "last": "Berschling", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Cooper", "suffix": ""}, {"first": "T", "middle": ["J"], "last": "T\u00f6r\u00f6k", "suffix": ""}, {"first": "H", "middle": ["M"], "last": "Blumberg", "suffix": ""}], "year": 1997, "venue": "Infect Control Hosp Epidemiol", "volume": "674", "issn": "18", "pages": "109--114", "other_ids": {}}, "BIBREF89": {"ref_id": "b89", "title": "Increased risk of 677 human parvovirus B19 infection in day-care employees: a cohort study among pregnant workers during an 678 epidemic in Finland", "authors": [{"first": "H", "middle": [], "last": "Taskinen", "suffix": ""}, {"first": "M", "middle": [], "last": "Nuutila", "suffix": ""}, {"first": "R", "middle": [], "last": "Karikoski", "suffix": ""}, {"first": "K", "middle": [], "last": "Hedman", "suffix": ""}, {"first": "M", "middle": [], "last": "S\u00f6derlund-Venermo", "suffix": ""}], "year": 2014, "venue": "Occup Environ Med", "volume": "71", "issn": "", "pages": "836--841", "other_ids": {"DOI": ["10.1136/oemed-2014-102217"]}}, "BIBREF90": {"ref_id": "b90", "title": "Covid-19: doctors in final trimester of pregnancy should avoid direct patient contact", "authors": [{"first": "A", "middle": [], "last": "Rimmer", "suffix": ""}], "year": null, "venue": "BMJ", "volume": "680", "issn": "2020", "pages": "", "other_ids": {"DOI": ["10.1136/bmj.m1173"]}}, "BIBREF91": {"ref_id": "b91", "title": "Pregnancy and Susceptibility to Infectious Diseases. Infectious 682 Diseases in", "authors": [{"first": "E", "middle": [], "last": "Sappenfield", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Jamieson", "suffix": ""}, {"first": "A", "middle": ["P"], "last": "Kourtis", "suffix": ""}], "year": 2013, "venue": "Obstetrics and Gynecology", "volume": "2013", "issn": "", "pages": "1--8", "other_ids": {"DOI": ["10.1155/2013/752852"]}}, "BIBREF92": {"ref_id": "b92", "title": "The congenital varicella syndrome", "authors": [{"first": "A", "middle": [], "last": "Sauerbrei", "suffix": ""}, {"first": "P", "middle": [], "last": "Wutzler", "suffix": ""}], "year": 2000, "venue": "J Perinatol", "volume": "20", "issn": "8", "pages": "548--554", "other_ids": {}}, "BIBREF93": {"ref_id": "b93", "title": "An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-685", "authors": [{"first": "D", "middle": ["A"], "last": "Schwartz", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF94": {"ref_id": "b94", "title": "Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes", "authors": [], "year": null, "venue": "Arch", "volume": "686", "issn": "", "pages": "", "other_ids": {}}, "BIBREF95": {"ref_id": "b95", "title": "Clinicopathologic analysis of 688 atypical hand, foot, and mouth disease in adult patients", "authors": [{"first": "J", "middle": [], "last": "Second", "suffix": ""}, {"first": "C", "middle": [], "last": "Velter", "suffix": ""}, {"first": "S", "middle": [], "last": "Cal\u00e8s", "suffix": ""}, {"first": "F", "middle": [], "last": "Truchetet", "suffix": ""}, {"first": "D", "middle": [], "last": "Lipsker", "suffix": ""}, {"first": "B", "middle": [], "last": "Cribier", "suffix": ""}], "year": 2017, "venue": "J. Am. Acad. Dermatol", "volume": "76", "issn": "", "pages": "722--729", "other_ids": {"DOI": ["10.5858/arpa.2020-0901-SA68790"]}}, "BIBREF97": {"ref_id": "b97", "title": "Clinical Presentations of Parvovirus B19 Infection", "authors": [{"first": "J", "middle": [], "last": "Servey", "suffix": ""}, {"first": "B", "middle": ["V"], "last": "Reamy", "suffix": ""}, {"first": "J", "middle": [], "last": "Hodge", "suffix": ""}], "year": 2007, "venue": "AFP", "volume": "75", "issn": "", "pages": "373--691", "other_ids": {}}, "BIBREF98": {"ref_id": "b98", "title": "Intrauterine viral infections 3", "authors": [{"first": "J", "middle": [], "last": "Sever", "suffix": ""}, {"first": "L", "middle": ["R"], "last": "White", "suffix": ""}], "year": 1968, "venue": "Annu Rev Med", "volume": "19", "issn": "", "pages": "471--486", "other_ids": {"DOI": ["10.1146/annurev.me.19.020168.002351"]}}, "BIBREF99": {"ref_id": "b99", "title": "Immunization of health-care personnel: Recommendations of the 695", "authors": [{"first": "A", "middle": [], "last": "Shefer", "suffix": ""}, {"first": "W", "middle": [], "last": "Atkinson", "suffix": ""}, {"first": "C", "middle": [], "last": "Friedman", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF100": {"ref_id": "b100", "title": "Advisory Committee on Immunization Practices (ACIP)", "authors": [], "year": 2011, "venue": "MMWR Recomm Rep", "volume": "60", "issn": "7", "pages": "1--45", "other_ids": {}}, "BIBREF101": {"ref_id": "b101", "title": "Guideline for Isolation Precautions: Preventing 697 Transmission of Infectious Agents in Health Care Settings", "authors": [{"first": "J", "middle": ["D"], "last": "Siegel", "suffix": ""}, {"first": "E", "middle": [], "last": "Rhinehart", "suffix": ""}, {"first": "M", "middle": [], "last": "Jackson", "suffix": ""}, {"first": "L", "middle": [], "last": "Chiarello", "suffix": ""}], "year": 2007, "venue": "American Journal of Infection Control", "volume": "698", "issn": "10", "pages": "65--164", "other_ids": {"DOI": ["10.1016/j.ajic.2007.10.007"]}}, "BIBREF102": {"ref_id": "b102", "title": "Low birth weight and maternal virus diseases: A prospective study of rubella, 700 measles, mumps, chickenpox, and hepatitis", "authors": [{"first": "M", "middle": [], "last": "Siegel", "suffix": ""}, {"first": "H", "middle": ["T"], "last": "Fuerst", "suffix": ""}], "year": 1966, "venue": "JAMA", "volume": "197", "issn": "9", "pages": "680--684", "other_ids": {"DOI": ["10.1001/jama.1966.03110090044013"]}}, "BIBREF103": {"ref_id": "b103", "title": "Congenital malformations following chickenpox, measles, mumps, and hepatitis. Results of a 703 cohort study", "authors": [{"first": "M", "middle": [], "last": "Siegel", "suffix": ""}], "year": 1973, "venue": "JAMA", "volume": "226", "issn": "13", "pages": "1521--1524", "other_ids": {}}, "BIBREF104": {"ref_id": "b104", "title": "Varicella in the fetus and newborn. Seminars in Fetal and Neonatal Medicine", "authors": [{"first": "C", "middle": ["K"], "last": "Smith", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Arvin", "suffix": ""}], "year": 2009, "venue": "", "volume": "705", "issn": "", "pages": "209--217", "other_ids": {"DOI": ["10.1016/j.siny.2008.11.008"]}}, "BIBREF106": {"ref_id": "b106", "title": "Hand-Foot-Mouth Disease", "authors": [], "year": null, "venue": "JAMA Dermatol", "volume": "149", "issn": "", "pages": "1419--1421", "other_ids": {}}, "BIBREF108": {"ref_id": "b108", "title": "Type-specific antibodies to herpes simplex virus type 2 710 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and 711 infants with neonatal herpes", "authors": [{"first": "W", "middle": ["M"], "last": "Sullender", "suffix": ""}, {"first": "L", "middle": ["L"], "last": "Yasukawa", "suffix": ""}, {"first": "M", "middle": [], "last": "Schwartz", "suffix": ""}], "year": 1988, "venue": "J Infect Dis", "volume": "157", "issn": "", "pages": "164--171", "other_ids": {"DOI": ["10.1093/infdis/157.1.164"]}}, "BIBREF111": {"ref_id": "b111", "title": "Human parvovirus B19 nosocomial outbreak in healthcare 715 personnel in a paediatric ward at a national tertiary referral centre in Thailand", "authors": [{"first": "N", "middle": [], "last": "Kongstan", "suffix": ""}, {"first": "K", "middle": [], "last": "Chokephaibulkit", "suffix": ""}], "year": 2017, "venue": "Journal of Hospital Infection", "volume": "716", "issn": "96", "pages": "163--167", "other_ids": {"DOI": ["10.1016/j.jhin.2017.03.014"]}}, "BIBREF113": {"ref_id": "b113", "title": "Risk Factors for Parvovirus B19 Infection in Pregnancy", "authors": [{"first": "B", "middle": ["N"], "last": "Pedersen", "suffix": ""}, {"first": "M", "middle": [], "last": "Melbye", "suffix": ""}], "year": 1999, "venue": "JAMA", "volume": "281", "issn": "", "pages": "719--1099", "other_ids": {"DOI": ["10.1001/jama.281.12.1099"]}}, "BIBREF115": {"ref_id": "b115", "title": "Adverse pregnancy and neonatal outcomes associated with 722", "authors": [{"first": "J", "middle": ["M"], "last": "Kaldor", "suffix": ""}, {"first": "N", "middle": [], "last": "Low", "suffix": ""}, {"first": "A", "middle": ["J"], "last": "Vallely", "suffix": ""}], "year": 2018, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF116": {"ref_id": "b116", "title": "Ureaplasma urealyticum and U. parvum: a 723 systematic review and meta-analysis protocol", "authors": [{"first": "", "middle": [], "last": "Neisseria Gonorrhoeae", "suffix": ""}, {"first": "M", "middle": [], "last": "Mycoplasma Genitalium", "suffix": ""}, {"first": "", "middle": [], "last": "Hominis", "suffix": ""}], "year": null, "venue": "BMJ Open", "volume": "8", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1136/bmjopen-7242018-024175"]}}, "BIBREF117": {"ref_id": "b117", "title": "Diagnosis and management of pityriasis rosea", "authors": [{"first": "K", "middle": [], "last": "Vanravenstein", "suffix": ""}, {"first": "B", "middle": ["J"], "last": "Edlund", "suffix": ""}], "year": 2017, "venue": "Nurse Pract", "volume": "42", "issn": "1", "pages": "8--11", "other_ids": {"DOI": ["10.1097/01.NPR.0000511012.21714.66"]}}, "BIBREF118": {"ref_id": "b118", "title": "Update on hand-foot-and-mouth disease", "authors": [{"first": "D", "middle": [], "last": "Ventarola", "suffix": ""}, {"first": "L", "middle": [], "last": "Bordone", "suffix": ""}, {"first": "N", "middle": [], "last": "Silverberg", "suffix": ""}], "year": 2015, "venue": "Clinics in", "volume": "728", "issn": "", "pages": "", "other_ids": {}}, "BIBREF121": {"ref_id": "b121", "title": "Mandatory influenza vaccination for all healthcare personnel: a review on 731 justification, implementation and effectiveness. Current Opinion in Pediatrics", "authors": [{"first": "T", "middle": ["L"], "last": "Wang", "suffix": ""}, {"first": "L", "middle": [], "last": "Jing", "suffix": ""}, {"first": "Jaj", "middle": [], "last": "Bocchini", "suffix": ""}], "year": 2017, "venue": "", "volume": "29", "issn": "", "pages": "606--615", "other_ids": {"DOI": ["10.1097/MOP.0000000000000527"]}}, "BIBREF122": {"ref_id": "b122", "title": "Pityriasis rosea is associated with systemic active infection with 734 both human herpesvirus-7 and human herpesvirus-6", "authors": [{"first": "T", "middle": [], "last": "Watanabe", "suffix": ""}, {"first": "T", "middle": [], "last": "Kawamura", "suffix": ""}, {"first": "S", "middle": ["E"], "last": "Jacob", "suffix": ""}], "year": 2002, "venue": "J Invest Dermatol", "volume": "119", "issn": "", "pages": "", "other_ids": {}}, "BIBREF123": {"ref_id": "b123", "title": "Varicella Vaccine Exposure during Pregnancy: Data from 10 Years of 736 the Pregnancy Registry", "authors": [{"first": "E", "middle": [], "last": "Wilson", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Goss", "suffix": ""}, {"first": "M", "middle": [], "last": "Marin", "suffix": ""}], "year": 2008, "venue": "J INFECT DIS", "volume": "197", "issn": "s2", "pages": "178--184", "other_ids": {"DOI": ["10.1086/522136"]}}, "BIBREF124": {"ref_id": "b124", "title": "Pregnancy and perinatal outcomes of women with severe acute 738 respiratory syndrome", "authors": [{"first": "S", "middle": ["F"], "last": "Wong", "suffix": ""}, {"first": "K", "middle": ["M"], "last": "Chow", "suffix": ""}, {"first": "T", "middle": ["N"], "last": "Leung", "suffix": ""}], "year": 2004, "venue": "American Journal of Obstetrics and Gynecology", "volume": "191", "issn": "1", "pages": "292--297", "other_ids": {"DOI": ["10.1016/j.ajog.2003.11.019"]}}, "BIBREF125": {"ref_id": "b125", "title": "World Health Organization. Varicella and herpes zoster vaccines: WHO position paper", "authors": [], "year": 2014, "venue": "", "volume": "89", "issn": "", "pages": "265--87", "other_ids": {"DOI": ["10.1016/j.vaccine.2014.07.068"]}}, "BIBREF126": {"ref_id": "b126", "title": "Disseminated Herpesvirus Infection During Pregnancy", "authors": [{"first": "E", "middle": ["J"], "last": "Young", "suffix": ""}, {"first": "E", "middle": [], "last": "Chafizadeh", "suffix": ""}, {"first": "V", "middle": ["L"], "last": "Oliveira", "suffix": ""}, {"first": "R", "middle": ["M"], "last": "Genta", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF128": {"ref_id": "b128", "title": "Maternal outcomes in pregnancies affected by varicella zoster", "authors": [{"first": "H", "middle": ["J"], "last": "Zhang", "suffix": ""}, {"first": "V", "middle": [], "last": "Patenaude", "suffix": ""}, {"first": "H", "middle": ["A"], "last": "Abenhaim", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "Association, 2015), a significant portion of both female trainees and attending 23 physicians are of childbearing age. In particular, dermatologists, pediatricians, and other health 24 care workers (HCWs) in these offices routinely care for patients who present with infections with 25 cutaneous manifestations. For pregnant HCWs, balancing patient care responsibilities and 26 occupational safety can be challenging, especially when the risk of transmission in the clinical 27 setting is unknown. To our knowledge, there is no comprehensive review of the literature that 28 specifically identifies risk of transmission of common exanthematous diseases to pregnant 29", "latex": null, "type": "figure"}, "FIGREF1": {"text": "range of clinical manifestations have been associated with parvovirus B19 40 (PVB19) infection, including erythema infectiosum, arthropathy and aplastic crisis. Erythema 41 infectiosum is the most common dermatologic manifestation of PVB19, presenting in children 42 between the ages of 5 and 14 following a prodrome. The classic presentation involves a facial 43 rash with a \"slapped-cheek\" appearance, followed by a morbilliform eruption on the extremities 44 and trunk one to four days later. Once the rash appears, patients are no longer contagious (Servey 45 et al., 2007). As such, while providers are at risk of infection during the PVB19 prodromal 46 phase, they are likely protected if patients present with rash. While the disease course itself is self-limiting, PVB19 infection during pregnancy has 48 been attributed to several adverse fetal outcomes including intrauterine fetal demise, 49 thrombocytopenia and hydrops fetalis. Transmission occurs primarily via exposure to droplets 50 and fomites but can also occur via vertical transmission. The rate of baseline immunity to PVB19 51 in pregnant populations ranges from 35% to 65% (Gillespie et al., 1990, Gratac\u00f3s et al., 1995, 52 Valeur-Jensen et al., 1999). The incidence of acute PVB19 infection in susceptible pregnant 53 women is reported to be 1-2%, with an estimated vertical transmission rate of approximately 25-54 35% (Gratac\u00f3s et al., 1995, Neu et al., 2015). Risks for childcare workers, including school 55 teachers and day-care center employees, is well documented in the literature (Riipinen et al., 56 2014). A population-based cohort study in Denmark of over 30,000 pregnant women found that 57 working as a nursery school teacher and having more children in the household were among the 58 greatest risk factors associated with acquiring parvovirus infection (Valeur-Jensen, et al., 1999).", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Various case reports and case series (Harrison and Jones, 1995, Lara-Medrano et al., 2016, 61 Sungkate et al., 2017) have demonstrated risk of transmission of parvovirus infection to HCWs62", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Although outbreaks of HFMD have been regularly reported worldwide in children,94 symptomatic infections in adults are less common (Chang et al., 2004). Individual cases of adult 95 infection have been reported in the literature (Murase and Akiyama, 2018, Stewart et al., 2013).", "latex": null, "type": "figure"}, "FIGREF4": {"text": "Coxsackievirus A6 (CVA6) serotype has been linked to several HFMD outbreaks 97 worldwide, affecting both adults and children (Kimmis et al., 2018, Ramirez-Fort et al., 2014). 98 HFMD due to CVA6 differs in presentation from classic HFMD. Unlike in typical HFMD, adults 99 with CVA6 HFMD are more likely to develop vesicular eruptions involving the dorsal hands and 100 feet, as well as the face (Horsten et al., 2018). The lesions may also appear more purpuric than 101 typical HFMD and can mimic secondary syphilis. Later in the disease process, the rash can 102 desquamate and mimic fungal infection (Ramirez-Fort et al., 2014). Other features include 103 widespread vesiculobullous and erosive lesions extending beyond the palms and soles, an 104 eczema herpeticum-like eruption termed \"eczema coxsackium\", and an eruption similar to 105 Gianotti-Crosti in children (Mathes et al., 2013). There can also be occasional sparing of the oral 106 mucosa (Second et al., 2017). Outbreaks of HFMD in adults that have been reported in the 107 literature have typically occurred in adults following exposure to children with HFMD (CDC 108 MMWR, 2012) or among college students (Buttery et al., 2015) and military trainees (Banta et 109 al., 2016).", "latex": null, "type": "figure"}, "FIGREF5": {"text": "110HFMD in pregnancy has been rarely reported in the literature and is largely limited to111 case reports (Chow et al., 2000, Deeb et al., 2019, Ogilvie and Tearne, 1980), with no reports 112 discussing pregnant HCWs specifically. One report identifies fetal demise secondary to maternal 113 Coxsackievirus A16 infection with confirmed massive placental perivillous fibrinoid deposition 114 (Heller et al., 2015), while another found no evidence to suggest that HFMD impacted pregnancy 115 course or newborn development (Second et al., 2017). A retrospective observational study in 116 Italy of 128 pregnant patients with clinically suspected HFMD or documented exposure found no 117 conclusive evidence that HFMD impacted fetal or neonatal outcomes (Giache et al., 2019). The 118 CDC also reports no clear evidence that non-polio enterovirus infection during pregnancy 119 increases risk of severe complications including miscarriage, stillbirth or congenital defects 120 (CDC, 2019).", "latex": null, "type": "figure"}, "FIGREF6": {"text": "the rate of HFMD is high among children, transmission to adults is less likely 123 and often confers an asymptomatic or milder course. The literature regarding HFMD outcomes in 124 pregnant women is limited. As such, we recommend proper and consistent hand hygiene and 125 strict droplet and contact precautions for any pregnant HCW who participates in the care of a 126 suspected HFMD case. It is also prudent to inform the HCW's obstetric provider for close 127 monitoring (Ventarola et al., 2015). If case is severe and requires hospitalization, we recommend 128 isolation of patient. If possible, we recommend having another provider to assume care for 129 HFMD patients in these cases.", "latex": null, "type": "figure"}, "FIGREF7": {"text": "are associated with various adverse outcomes in pregnancy.", "latex": null, "type": "figure"}, "FIGREF8": {"text": "Although the incidence of Mycoplasma pneumoniae infection in pregnancy is unknown134 (Matsuda et al., 2017), pneumonia during pregnancy is well-associated with preterm labor and 135 low birth weight (Chen et al., 2013). Mycoplasma-induced rash and mucositis (MIRM) refers to Mycoplasma pnuemoniae 137 associated mucocutaneous disease with prominent mucositis and varying degrees of cutaneous 138 involvement (Canavan et al., 2015). Classically, MIRM presents as severe conjunctivitis and 139 blepharitis, severe oral mucositis with hemorrhagic crusting, and sparse vesiculobullous eruption 140 in children and adolescents with a 2:1 male to female predominance (Canavan et al., 2015). To 141 our knowledge, there are no reports in the literature of MIRM occurring during pregnancy. Care 142 for MIRM patients involves supportive care including fluids, analgesia, and ophthalmology and 143 urology evaluation (Canavan et al., 2015).", "latex": null, "type": "figure"}, "FIGREF9": {"text": "knowledge, MIRM has not been reported in a pregnant patient or HCW. We 146 recommend dermatology consultation if HCW is symptomatic following exposure to patients 147 with mycoplasma manifesting as MIRM, with close monitoring of symptom resolution.", "latex": null, "type": "figure"}, "FIGREF10": {"text": "Treatment should be similar to that for a non-pregnant patient with MIRM, which includes149 evaluation and monitoring by a physician, antibiotics, systemic corticosteroids, or rarely, 150 intravenous immunoglobulin (IVIG) administration.", "latex": null, "type": "figure"}, "FIGREF11": {"text": "incidence of measles has climbed in recent years. Sizeable outbreaks continue 153 to occur around the world, largely due to decreased vaccination rates. While the skin 154 manifestations of measles are non-diagnostic, it is increasingly important that HCWs be able to 155 recognize the disease.156The clinical manifestations of measles virus infection classically begin with a prodrome 157 characterized by fever, malaise, cough, coryza, and conjunctivitis. Koplik spots may appear 158 during the prodromal phase. An erythematous, morbilliform exanthem appears approximately 159 three to five days after the onset of symptoms with cranial to caudal progression. The patient is 160 considered contagious from four days before and after the appearance of the rash. Notably, 161 exanthem may be absent in immunocompromised patients and pregnant women, making measles 162 more difficult to recognize.163    Measles during pregnancy has been associated with increased risk of adverse maternal,164 fetal, and neonatal outcomes. One retrospective cohort analysis of 55 pregnant women with 165 measles in Namibia showed increased risks for low birth weight, spontaneous abortion, 166 intrauterine fetal death, and maternal death when compared with pregnancies without measles 167 (Ogbuanu et al., 2014). In this study, 71% of the women developed measles-related 168 complications, including diarrhea (60%), pneumonia (40%), and encephalitis (5%). Of the 169 pregnancies with known outcomes, 60% had at least one adverse outcome, including maternal 170 death in 12% of cases. Other studies comparing women with and without measles during 171 pregnancy have shown increased frequency of prematurity, increased likelihood of neonatal 172 intensive care unit admission, and longer intensive care unit stays among neonates born to mothers 173 with gestational measles (Siegel and Fuerst, 1966; Ali and Albar, 1997). The rate of congenital 174 defects does not appear to be higher among neonates born to mothers with measles than to 175 uninfected mothers (Siegel, 1973; Ali and Albar, 1997). However, congenital measles can occur, 176 with the severity ranging from mild to fatal (Gershon 2006). Congenital measles has been 177 reported among neonates born to women who had measles within 10 days of delivery (Charlier et 178 al., 2015). Measles is highly contagious, with up to 90% of susceptible individuals becoming 179 infected upon exposure (McLean et al., 2013). HCWs are at higher risk of being exposed to, and 180 subsequently developing, measles than the general adult population (Shefer et al., 2011).", "latex": null, "type": "figure"}, "FIGREF12": {"text": "should provide evidence of immunity to measles prior to employment, and 183 non-pregnant HCWs should receive the measles, mumps and rubella (MMR) vaccine in the 184 absence of such evidence (Bolyard et al., 1998; Siegel et al., 2007; McLean et al., 2013). Women 185 should avoid becoming pregnant for four weeks following vaccination (McLean et al., 2013). 186 MMR vaccine is contraindicated during pregnancy due to the theoretical risk of live vaccines to 187 the fetus, though inadvertent MMR vaccination during pregnancy has not been associated with 188 an increased risk of adverse outcomes and is not an indication for pregnancy termination (Bar-Oz 189 et al., 2004). Close contacts of pregnant women should ensure their MMR titers are sufficient or 190 receive an MMR vaccination or booster. 191 Pregnant HCWs without evidence of measles immunity (seronegative), like all 192 susceptible HCWs, should not enter the rooms of patients with known or suspected measles 193 (Siegel et al., 2007). If exposed to measles, nonimmune pregnant women should receive 194 intravenous immunoglobulin (IVIG) treatment within 6 days of exposure (Siegel et al., 2007). 195 Any exposed HCW without evidence of immunity should be excluded from the healthcare 196 setting from the 5th through 21st days after exposure (Bolyard et al., 1998; Shefer et al., 2011). If 197 immune, pregnant HCWs may care for measles patients and should follow airborne and standard 198 precautions, with respiratory protection at least as protective as a fit-tested N95 respirator 199 (Bolyard et al., 1998; Siegel et al., 2007; Shefer et al., 2011).", "latex": null, "type": "figure"}, "FIGREF13": {"text": "of herpes simplex virus (HSV) infection vary widely. HSV-1 202typically causes orofacial infection, while HSV-2 is predominantly responsible for genital203    herpes. However, each viral subtype can affect either anatomic location. Genital herpes is of 204 concern to pregnant women given the risk of vertical transmission and the morbidity and 205 mortality associated with congenital and neonatal infection. When symptomatic, genital herpes 206 presents as painful, pruritic vesicles and ulcers, which may be accompanied by headache, fever, 207 dysuria, and tender inguinal lymphadenopathy. Recurrences are typically milder than primary 208 infection, and even primary infection may be subclinical.209Data suggest that at least two percent of susceptible women in the U.S. acquire HSV 210 during pregnancy(Brown et al., 1997). Primary HSV infection during pregnancy may rarely lead 211 to life-threatening disseminated disease(Young et al., 1996;Sappenfield et al., 2013), but the 212 greatest risk is vertical transmission. Intrauterine infection is rare, but its occurrence is associated 213 with severe neurological, ophthalmologic, and cutaneous manifestations, as well as a high risk of214 intrauterine or postnatal death (Marquez et al., 2011). More commonly, transmission of HSV to 215 the child is due to contact with virus shed from the genital or perianal region during labor and 216 delivery. 50% to 80% of cases of neonatal HSV infection occur when genital HSV-1 or HSV-2 217 infection is acquired near term (Brown et al., 1997; Sullender et al., 1988). The risk is greatest 218 when HSV is acquired within six weeks of delivery, when there is insufficient time for 219 transplacental delivery of maternal antibodies (Brown et al., 1997). Transmission to the neonate 220 is far less frequent among women who acquire genital herpes during early pregnancy or with 221 histories of recurrent herpes, even if lesions are present at the time of delivery (Prober et al., 222 1987; Foley et al., 2014). Women with a history of HSV should be offered daily suppressive 223 acyclovir or valacyclovir starting at 36 weeks' gestation to reduce the likelihood of clinical 224 lesions and viral shedding at delivery (Money and Steben, 2017). Caesarean section is 225 recommended for women with primary genital herpes during the third trimester and for women 226 with histories of genital HSV and either active lesions or prodromal symptoms at the time of 227 labor (Money and Steben, 2017; Foley et al., 2014). Pregnant women should take appropriate 228 precautions to avoid acquiring genital HSV, especially during the third trimester. 229 Management Recommendations: 230 Occupational acquisition of HSV during pregnancy is unlikely due to low rates of 231 nosocomial HSV transmission, although contact with infectious lesions or secretions can lead to 232 the development of herpetic whitlow. HCWs who are pregnant or of childbearing age should be 233 counseled on the risks of HSV acquisition during pregnancy, which may pose a danger to the 234 fetus. However, HCWs should not be routinely excluded from caring for patients with HSV 235 solely on the basis of their pregnancy or intent to become pregnant (Bolyard et al., 1998). Non-236 genital herpes poses minimal risk to the fetus given the low rate of intrauterine infection, and 237 transmission of genital herpes is not an occupational concern as it requires sexual contact. All 238 HCWs should follow standard precautions when caring for patients with HSV infection, and 239 additional contact precautions are advised in certain high-risk cases, such as if the HCW is 240 immunocompromised or if the patient has severe, disseminated HSV (Bolyard et al., 1998; 241 Siegel et al., 2007). 242 Varicella zoster virus: 243 Varicella zoster virus (VZV) is responsible for varicella (chickenpox) during primary 244 infection and herpes zoster (shingles) upon reactivation. Varicella is typically a mild disease in 245 children, presenting as a diffuse vesicular rash. The rash is often pruritic and consists of lesions 246 at different stages of development. A prodrome of fever, malaise, and myalgia may precede the 247 exanthem. Primary infection is associated with higher morbidity and mortality when it occurs 248 during adulthood, especially in immunocompromised patients and pregnant women. Varicella 249 during pregnancy poses additional risks to the neonate. Herpes zoster typically manifests as a 250 painful and unilateral maculopapular rash whose lesions follow a dermatomal distribution, 251 evolving into vesicles that eventually crust within seven to ten days. Herpes zoster during 252 pregnancy is not associated with birth defects or disease in the infant (Enders et al., 1994; Smith 253 and Arvin, 2009). 254 Varicella is highly contagious. Patients are considered infectious from 48 hours prior to 255 the onset of rash until the skin lesions have fully crusted. The incidence of varicella is not 256 thought to be higher among pregnant women than nonpregnant adults, and previous reports of 257 greater severity have not been supported by recent studies (Sappenfield et al., 2013). The 258 incidence of VZV infection in pregnancy has been estimated at 0.7 to 3 per 1,000 pregnancies 259 (Miller et al., 1993; Sever and White, 1968). Varicella pneumonia is considered the most 260 significant complication of varicella during pregnancy, though a recent large cohort study found 261 the incidence (2.5%) and maternal mortality (0%) to be lower than previously estimated (Zhang 262 et al., 2015). 263 Transmission of VZV to the fetus can occur in utero, perinatally, or postnatally (Enright 264 and Prober, 2004). Maternal varicella infection during early pregnancy introduces the risk of 265 fetal varicella syndrome (FVS), with the greatest risk (2%) when infection occurs between 13 266 and 20 weeks of gestation (Enders et al., 1994; Harger et al., 2002; Pastuszak et al., 1994). 267 Characteristic findings in FVS include cutaneous scars in a dermatomal distribution, low birth 268 weight, neurological abnormalities, ocular defects, and limb deformities. FVS is associated with a 269 mortality rate of 30% during the first few months of life (Sauerbrei and Wutzler, 2000). Varicella 270 during the second and third trimesters presents a small risk of herpes zoster during infancy or 271 early childhood (Enders, et al. 1994). Maternal varicella occurring from five days before delivery 272 to two days after delivery may result in severe neonatal varicella (Smith and Arvin, 2009), 273 characterized by fever, vesicular lesions in various stages of development, and potential 274 progression to disseminated disease (e.g., varicella pneumonia, hepatitis, meningioencephalitis). 275 Management Recommendations: 276 Nonpregnant HCWs without evidence of immunity (seronegative) to VZV should receive 277 the varicella vaccine unless otherwise contraindicated (Shefer et al., 2011). Women should avoid 278 becoming pregnant for one month following each injection (Marin et al., 2007). The vaccine is 279 contraindicated in pregnancy due to the theoretical risk of live vaccines to the fetus (Marin et al., 280 2007), though inadvertent vaccination during pregnancy has not been associated with an 281 increased risk of congenital anomalies (Wilson et al., 2008) and is not an indication for 282 pregnancy termination (Ezeanolue et al.; World Health Organization, 2014). Prenatal assessment 283 for immunity to VZV is recommended for all pregnant women (Marin et al., 2007). Varicella 284 vaccine should be administered postpartum to nonimmune pregnant HCWs (Marin et al., 2007).", "latex": null, "type": "figure"}, "FIGREF14": {"text": "Breastfeeding women may be vaccinated safely(Marin et al., 2007). Pregnant HCWs with no286 evidence of immunity, like all susceptible HCWs, should avoid contact with patients with 287 confirmed or suspected varicella or herpes zoster (Siegel et al., 2007; Shefer et al., 2011; Chin et 288 al., 2014; Kim et al., 2018). Immunized pregnant HCWs should follow airborne and contact 289 precautions when caring for patients with varicella or disseminated herpes zoster; the same is 290 true when caring for immunocompromised patients with localized zoster until disseminated 291 infection has been ruled out. Because airborne transmission from immunocompetent patients 292 with localized zoster is unlikely, it is sufficient for immunized HCWs to follow standard 293 precautions and cover all lesions until dry and crusted. (Bolyard et al., 1998; Shefer et al., 2011).", "latex": null, "type": "figure"}, "FIGREF15": {"text": "295exposure(Shefer et al., 2011). If a susceptible pregnant HCW is exposed, varicella-zoster 296 immune globulin (e.g., VariZIG) should be administered as soon as possible, ideally within 96 297 hours but up to 10 days after exposure(Marin et al., 2013). Susceptibility should be confirmed298 by serology prior to administration if possible. Careful monitoring for signs of infection despite 299 passive immunization is essential. Nonimmune HCWs should be furloughed during days 8-28 300 after exposure (Shefer et al., 2011). If symptoms of varicella or disseminated zoster develop, 301 HCWs should be placed on sick leave until all lesions have crusted over (Shefer et al., 2011; 302 Chin et al., 2014; Kim et al., 2018). Fetal and maternal monitoring is crucial. Some experts 303 recommend that pregnant women with uncomplicated varicella should receive oral acyclovir. In 304 pregnant women with varicella pneumonia or other serious complications, intravenous acyclovir 305 is advised (American Academy of Pediatrics Committee on Infectious Diseases, 2012; M\u00fcllegger 306 et al., 2016).", "latex": null, "type": "figure"}, "FIGREF16": {"text": "rosea (PR) is an acute, self-limiting papulosquamous disorder that 309 characteristically begins with the appearance of a small, isolated, oval plaque referred to as the 310 \"herald patch\". A generalized eruption of smaller, but morphologically similar lesions appears on 311 the trunk and proximal extremities within one to two weeks. Their long axes are classically 312 oriented to create a \"Christmas tree\" pattern on the back or a V-shaped pattern on the upper 313 chest. Oropharyngeal lesions may rarely be present. Prodromal symptoms may precede the 314 exanthem. Pruritus is reported in approximately 50% of cases (Eisman and Sinclair, 2015), but 315 PR otherwise tends to be asymptomatic and usually resolves spontaneously within four to eight 316 weeks.", "latex": null, "type": "figure"}, "FIGREF17": {"text": "Watanabe et al., 2002; Broccolo et al., 2005; Drago et al., 2009), though many patients 323 show no evidence of active infection with HHV-6/7, and several other viruses (including 324 reactivated HSV-2 in the case of a pregnant woman) have been implicated anecdotally in the 325 pathogenesis of PR (Cruz et al., 2011). 326 PR occurs most commonly between the ages of 10 and 35 (Eisman and Sinclair, 2015) 327 with an approximate incidence of 0.5% to 2% (VanRavenstein and Edlund, 2017). It 328 disproportionately affects pregnant women compared with young, non-pregnant women (Corson, 329 1950), possibly due to increased susceptibility to HHV-6/7 reactivation in the setting of altered 330 immunity. 331 There are several reports of healthy, uncomplicated deliveries in patients with PR in the 332 literature (Corson, 1950; Overton, 1968; Chuh et al., 2005; Bianca et al., 2007). However, a large 333 case series following 61 patients with gestational PR showed an association with adverse 334 outcomes (Drago et al., 2008; Drago et al., 2014). The overall miscarriage rate among these 335 cases was 13% but rose to 57% if PR developed during the first 15 weeks of gestation. The series 336 suggested that viral reactivation of HHV-6 may have led to intrauterine transmission and 337 subsequent fetal loss. Other unfavorable fetal outcomes reported included premature delivery and 338 neonatal hypotonia. PR development before gestational week 15, the presence of enanthem, and 339 high HHV-6 viral load were classified as major risk factors for poor outcomes. Constitutional 340 symptoms and involvement of >50% of body surface area were considered minor risk factors 341 (Drago et al., 2018). Atypical forms of PR may be associated with prolonged viral reactivation in 342 the plasma and potential intrauterine transmission (Drago et al., 2016). The risk of maternal 343 HHV-6 reactivation and intrauterine transmission has been described by others, but low rates of 344 congenital infection (~1%) were reported; furthermore, most congenital infections occurred due 345 to chromosomal integration rather than transplacental infection (Caserta et al., 2007; Caserta et 346 al., 2014). Further studies are needed to substantiate the findings made by Drago's group and 347 elucidate the effects of PR on pregnancy outcomes. 348 Management Recommendations: 349 Recommendations in the literature regarding PR during pregnancy are sparse and based 350 on a paucity of evidence. Differential diagnoses should be ruled out, with particular attention 351 given to excluding secondary syphilis. Syphilis should especially be considered if a rash is 352 present on the palms or soles. Serological screening for syphilis is strongly recommended for all 353 pregnant women with suspected PR, as there is a serious risk of congenital infection if not 354 promptly treated (Chuh et al., 2005; Mahajan et al., 2016). Drug-related PR-like eruptions should 355 also be considered, as these are not associated with viral reactivation and may not pose the same 356 risk to the fetus (Drago et al., 2016). There is one reported case of a PR-like drug eruption due to 357 ondansetron use in a pregnant woman with nausea and vomiting (Alame et al., 2018), but many 358 other drugs are known to cause such eruptions.", "latex": null, "type": "figure"}, "FIGREF19": {"text": "However, there are special recommendations for management of pregnant women. Particularly362 close monitoring is called for if the mother develops PR within the first 15-20 weeks of gestation 363 or experiences constitutional symptoms or an unusually diffuse, prolonged rash (Drago et al., 364 2008; Drago et al., 2014; Drago et al., 2016; Monastirli et al., 2016). In these cases of atypical 365 PR in pregnant women, conflicting recommendations exist in the literature. Some recommend 366 avoiding systemic therapy (Mahajan et al., 2016), while others recommend considering the use 367 of acyclovir (Drago et al., 2015; Chuh et al., 2016; Drago et al., 2018), which has been shown to 368 hasten the resolution of PR lesions and relieve pruritus. A low-dose regimen (400 mg three times 369 daily for 7 days) is recommended if such intervention is indicated. 370 Given the potential increased risk of miscarriage in the first 15 weeks of gestation, 371 pregnant HCWs should avoid contact with patients known to have PR during early stages of 372 pregnancy, if possible, and all pregnant HCWs should utilize appropriate contact precautions 373", "latex": null, "type": "figure"}, "FIGREF20": {"text": "2019, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) 378 has resulted in an increasingly devastating global pandemic. In response to the overwhelming 379 number of patients with the novel coronavirus disease (COVID-19) requiring hospitalization and 380 ICU-level care, many medical providers who do not traditionally perform roles in these settings 381 have been called to assist. The medical community's knowledge of COVID-19 continues to 382 evolve rapidly. Information regarding any potential dermatologic manifestations of the disease, 383 as well as the disease's impact on pregnancy, is limited as of April 2020. Pivotal data from 384 patients in Wuhan, China have revealed that cutaneous manifestations of COVID-19 are rare, 385 with only 2% of over 1,000 patients having any type of documented rash (Guan et al., 2020).", "latex": null, "type": "figure"}, "FIGREF21": {"text": "of 17 pregnant patients, including three HCWs, also did not find conclusive 392 evidence of vertical transmission(Khan et al., 2020). In a separate study of 13 pregnant patients 393 with COVID-19, researchers did not find evidence of vertical transmission but did note that five 394 patients required emergency cesarean section to avoid pregnancy-related complications(Liu et    395 al., 2020). Although data on pregnant women from previous coronavirus pandemics are limited, 396 it does not appear that pregnant women were more likely to acquire SARS-CoV-1 or MERS-397 CoV, other coronaviruses similar to SARS-CoV-2, which cause severe acute respiratory 398 syndrome (SARS) and Middle East Respiratory Syndrome (MERS), respectively (Rasmussen et 399 al., 2020). However, data from pregnant patients with SARS found that when pregnant women 400 actually did acquire SARS-CoV-1, they tended to have more neonatal and maternal 401 complications, including increased rates of ICU admission and mortality compared to non-402 pregnant patients (Lam et al. 2004; Wong et al., 2004).403 Management Recommendations: 404 As with all HCWs, pregnant HCWs should follow infection control recommendations 405 from public health officials and abide by occupational health and safety guidelines established by 406 the individual healthcare systems in which they work. Pregnant HCWs should not provide any 407 clinical care if they test positive for COVID-19. Any pregnant HCW who has symptoms 408 suggestive of COVID-19 should self-isolate following testing for SARS-CoV-2 until results are 409 available. The Royal College of Obstetricians and Gynaecologists (RCOG) recommends that 410 female HCWs who are more than 28 weeks pregnant should avoid direct contact with all patients 411 during the ongoing pandemic, even if the HCW is asymptomatic or has not had contact with 412 known or suspected COVID-19 patients (Rimmer, 2020). Those who are less than 28 weeks 413 pregnant, however, can continue to work in patient facing roles provided that they use proper 414 personal protection equipment (PPE) (Rimmer, 2020). Some individual institutions have chosen 415 to prohibit any pregnant HCW, whenever possible, from caring for patients with COVID-19. 416 General principles regarding management of COVID-10 during pregnancy include early 417 isolation, aggressive infection control procedures, testing for SARS-CoV-2 and coinfection, 418 oxygen therapy as needed, avoidance of fluid overload, empiric antibiotics (due to secondary 419 bacterial infection risk), fetal and uterine contraction monitoring, early mechanical ventilation 420 for progressive respiratory failure, individualized delivery planning, and a team-based approach 421 with multispecialty consultations (Rasmussen et al., 2020). Although breastfeeding is not 422 currently contraindicated in patients with COVID-19, it is recommended that patients wear a face 423 mask while breastfeeding to minimize risk of droplet transmission to the newborn (Dashraath et 424 al., 2020). While SARS-CoV-2 has yet to be identified in breastmilk, newborns are still 425 susceptible to transmission from contact with mothers or other family members, highlighting the 426 importance of proper hand hygiene and social distancing measures.427 Conclusion: 428 This review summarizes common exanthematous diseases that pregnant HCWs may be 429 exposed to in the clinical environment. Large trials on outcomes in pregnant women, especially 430 HCWs, are limited. As such, guidelines and recommendations for prevention for pregnant HCWs 431 are limited. Here, we have reviewed and summarized recommendations from the literature. 432 Further research is necessary to evaluate the impact of these measures on prevention. 433 Recommendations should ensure adequate protection for HCWs while limiting unnecessary or 434 cumbersome practices that would unnecessarily prevent pregnant HCWs from performing 435 clinical duties. In addition, vaccination prior to pregnancy of preventable diseases, such as 436 measles and varicella, is crucial. All clinicians should encourage women of childbearing 437 potential to receive appropriate vaccinations prior to conceiving. Although the CDC provides 438 vaccination recommendations for all HCWs (CDC MMWR, 2011), vaccination laws are 439 typically determined by individual countries or, in the case of the United States, at the state level.", "latex": null, "type": "figure"}, "FIGREF23": {"text": "Mandated vaccination requirements have been shown to be highly successful; for example, 442 influenza vaccination rates in HCWs have significantly increased when healthcare institution-443 based mandates have been implemented in conjunction with government mandated vaccination 444 requirements (Lin et al, 2016; Wang et al, 2017). All trainees, regardless of gender, should be 445 appropriately vaccinated prior to matriculation in health professional programs, and all HCWs 446 and trainees should demonstrate proof of current immunity prior to working at new sites or Charlier C, Hourrier S, Leruez-Ville M, et al. Polyvalent immunoglobulins in neonates after perinatal 502 exposure to measles. Journal of Infection. 2015;71(1):131-134. doi:10.1016/j.jinf.2015.01.010 503 22. Chen, Y.-H., Keller, J., Wang, I.-T., Lin, C.-C., Lin, H.-C., 2012. Pneumonia and pregnancy outcomes: a 504 nationwide population-based study. American Journal of Obstetrics and Gynecology 207, 288.e1-288.e7. 505 https://doi.org/10.1016/j.ajog.2012.08.023 506 23. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of 507 COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet.", "latex": null, "type": "figure"}, "FIGREF24": {"text": "Chin TL, MacGowan AP, Jacobson SK, Donati M. Viral infections in pregnancy: Advice for healthcare 510 workers. Journal of Hospital Infection. 2014;87(1):11-24. doi:10.1016/j.jhin.2013.12.011 511 25. Chow, K.-C., Lee, Chien-Chung, Lin, T.-Y., Shen, W.-C., Wang, J.-H., Peng, C.-T., Lee, Cheng-Chun, 512 2000. Congenital Enterovirus 71 Infection: A Case Study with Virology and Immunohistochemistry. Clin", "latex": null, "type": "figure"}, "FIGREF25": {"text": "Dis 31, 509-512. https://doi.org/10.1086/313975 514 26. Chuh A, Zawar V, Sciallis G, Kempf W. A position statement on the management of patients with 515 pityriasis rosea. Journal of the European Academy of Dermatology and Venereology. 2016;30(10):1670-516 1681. doi:10.1111/jdv.13826.", "latex": null, "type": "figure"}, "FIGREF26": {"text": "Chuh AAT, Lee A, Chan PKS. Pityriasis rosea in pregnancy -specific diagnostic implications and 518 management considerations. The Australian and New Zealand Journal of Obstetrics and Gynaecology.", "latex": null, "type": "figure"}, "FIGREF28": {"text": "Drago F, Ciccarese G, Rebora A, Parodi A. The efficacy of macrolides and acyclovir in pityriasis rosea.", "latex": null, "type": "figure"}, "FIGREF29": {"text": "Journal of Dermatology, Venereology, and Leprology. 2015 Jan-Feb;81(1):56. doi: 10.4103/0378-549 6323.148572.", "latex": null, "type": "figure"}, "FIGREF30": {"text": "Drago F, Ranieri E, Malaguti F, et al. Human herpesvirus 7 in patients with pityriasis rosea. Electron 551 microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin.", "latex": null, "type": "figure"}, "FIGREF32": {"text": "Eisman S, Sinclair R. Pityriasis rosea. Bmj. 2015. doi:10.1136/bmj.h5233.", "latex": null, "type": "figure"}, "FIGREF33": {"text": "Enders G, Bolley I, Miller E, Cradock-Watson J, Ridehalgh M. Consequences of varicella and herpes zoster 555 in pregnancy: Prospective study of 1739 cases. The Lancet. 1994;343(8912):1548-1551.", "latex": null, "type": "figure"}, "FIGREF34": {"text": "Enright AM, Prober CG. Herpesviridae infections in newborns: Varicella zoster virus, herpes simplex virus, 558 and cytomegalovirus. Pediatric Clinics of North America. 2004;51(4):889-908.", "latex": null, "type": "figure"}, "FIGREF35": {"text": "Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General Best Practice Guidelines for 561 Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP).", "latex": null, "type": "figure"}, "FIGREF36": {"text": "562www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/downloads/general-recs.pdf. Accessed on July 27, 2019.", "latex": null, "type": "figure"}, "FIGREF37": {"text": "Foley E, Clarke E, Beckett VA, et al. Royal College of Obstetricians & Gynaecologists. Management of 564 genital herpes in pregnancy. https://www.bashhguidelines.org/media/1060/management-genital-herpes.pdf.", "latex": null, "type": "figure"}, "FIGREF38": {"text": "October 2014. Accessed July 30, 2019.Gershon AA. Chickenpox, measles and mumps. In: 566 Infectious Diseases of the Fetus and Newborn Infant, 6th ed, Remington JS, Klein JO, Wilson CB, et al 567 (Eds), Elsevier Saunders, Philadelphia 2006. P.693.", "latex": null, "type": "figure"}, "FIGREF39": {"text": "Giach\u00e8, S., Borchi, B., Zammarchi, L., Colao, M.G., Ciccone, N., Sterrantino, G., Rossolini, G.M., 569 Bartoloni, A., Trotta, M., 2019. Hand, foot, and mouth disease in pregnancy: 7 years Tuscan experience and 570 literature review. J. Matern. Fetal. Neonatal. Med. 1-7. https://doi.org/10.1080/14767058.2019.1638898 571 47. Gillespie, S.M., Cartter, M.L., Asch, S., Rokos, J.B., Gary, G.W., Tsou, C.J., Hall, D.B., Anderson, L.J., 572 Hurwitz, E.S., 1990. Occupational Risk of Human Parvovirus B19 Infection for School and Day-care 573 Personnel During an Outbreak of Erythema Infectiosum. JAMA 263, 2061-2065.", "latex": null, "type": "figure"}, "FIGREF40": {"text": "Gratac\u00f3s, E., Torres, P.-J., Vidal, J., Antol\u00edn, E., Costa, J., Jimenez de Anta, M.T., Cararach, V., Alonso, 576 P.L., Fortuny, A., 1995. The Incidence of Human Parvovirus B19 Infection during Pregnancy and Its 577 Impact on Perinatal Outcome. J Infect Dis 171, 1360-1363. https://doi.org/10.1093/infdis/171.5.1360 578 49. Harger JH, Ernest JM, Thurnau GR, et al. Frequency of congenital varicella syndrome in a prospective virus infections: Population-based study on 7.7 million pregnancy admissions: Maternal outcomes of VZV 746 infections. J Obstet Gynaecol Res. 2015;41(1):62-68. doi:10.1111/jog.12479 747", "latex": null, "type": "figure"}, "TABREF0": {"text": ").Management Recommendations:It is recommended that pregnant HCWs should not be part of the care team for patients with suspected PVB19 infection if possible. If exposure is suspected, risk assessment should consider the presence of an ongoing outbreak, as well as the extent of contact that the HCW had with exposed patients. Droplet precautions should be strictly followed when caring for patients with PVB19. Please refer toTable 1for the different types of infection control and prevention precautions. If a pregnant HCW is exposed to a known or suspected parvovirus case, she shouldundergo PVB19 testing for IgM and IgG (Crowcroft et al., 1999; Katta 2002; Kho et al., 2008; Lamont et al., 2010). If IgM positive, pregnant HCW below 21 weeks of gestation should undergo serial ultrasound examinations scheduled per obstetrician recommendation to assess for development of fetal hydrops. Maternal IVIG administration is not recommended. Please refer toTable 2for a summary of infection risk, complications, prevention, and management guidelines.Hand, Foot and Mouth Disease:Hand, foot, and mouth disease (HFMD) is a highly contagious viral infection typically caused by Coxsackievirus A16 and Enterovirus 71 (EV71). The infection, which is primarily transmitted via respiratory droplets, contact with blisters, or contact with feces, most commonly affects children under the age of 5. It is classically characterized by a macular, morbilliform, or", "latex": null, "type": "table"}, "TABREF1": {"text": "2005;45(3):252-253. doi:10.1111/j.1479-828x.2005.00399.x. 28. Corson EF. Coincidence Of Pityriasis Rosea With Pregnancy. Archives of Dermatology. 1950;62(4):562. doi:10.1001/archderm.1950.01530170088012. 29. Crowcroft, N., Roth, C., Cohen, B., Miller, E., 1999. Guidance for control of parvovirus B19 infection in 523 healthcare settings and the community. Journal of Public Health 21, 439-446. https://doi.org/10.1093/pubmed/21.4.439 525 30. Cruz MJ, Baudrier T, Azevedo F. Atypical pityriasis rosea in a pregnant woman: First report associating 526 local herpes simplex virus 2 reactivation. The Journal of Dermatology. 2011;39(5):490-492. doi:10.1111/j.1346-8138.2011.01349.x. 31. Dashraath P, Jing Lin Jeslyn W, Mei Xian Karen L, et al. Coronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy. American Journal of Obstetrics and Gynecology. March 2020. doi:10.1016/j.ajog.2020.03.021 531 32. Data and Reports -Workforce -Data and Analysis -AAMC [WWW Document], n.d. URL https://www.aamc.org/data/workforce/reports/492560/1-3-chart.html (accessed 7.16.19). 33. Deeb, M., Beach, R.A., Kim, S., 2019. Onychomadesis following hand, foot, and mouth disease in a pregnant woman: A case report. SAGE Open Medical Case Reports 7, 2050313X1984520. https://doi.org/10.1177/2050313X19845202 536 34. Drago F, Broccolo F, Javor S, Drago F, Rebora A, Parodi A. Evidence of human herpesvirus-6 and -7 reactivation in miscarrying women with pityriasis rosea. Journal of the American Academy of Dermatology. 2014;71(1):198-199. doi:10.1016/j.jaad.2014.02.023. 35. Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible 540 herpesviral etiology. J Am Acad Dermatol 2009; 61:303. 36. Drago F, Broccolo F, Zaccaria E, et al. Pregnancy outcome in patients with pityriasis rosea. Journal of the American Academy of Dermatology. 2008;58(5). doi:10.1016/j.jaad.2007.05.030. 37. Drago F, Ciccarese G, Herzum A, Rebora A, Parodi A. Pityriasis Rosea during Pregnancy: Major and Minor Alarming Signs. Dermatology. 2018;234(1-2):31-36. doi:10.1159/000489879. 38. Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A. Pityriasis Rosea: A Comprehensive Classification.", "latex": null, "type": "table"}, "TABREF2": {"text": "Infection Control and Prevention Precautions Proper disinfection of equipment Source control (place mask on patient) Place patient in an airbone infection isolation room (or private room if airbone infection isolation room is unavailable) Restrict susceptible HCWs from entering patient room Use personal protective equipment (PPE) such as surgical face mask Limit transport of patient Source control (place mask on patient) Place patient in an airbone infection isolation room (or private room if airbone infection isolation room is unavailable) Restrict susceptible HCWs from entering the room Use PPE such as fit-tested N95 mask Limit transport of patient Immunize susceptible HCWs as soon as possible following unprotected contact if indicated Use of PPE, including glov and gown Place patient in private roo possible Limit transport of patient Use disposable or dedicate patient-care equipment Prioritize cleaning/disinfec of patient room Use proper hand washing to leaving patient room Pathogen/Dise ase", "latex": null, "type": "table"}}, "back_matter": []}